Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Apr
18
Today In Oncology
Melanoma Can AI Enable Diagnosis Prediction
AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers
DRUP Trial Investigates Use of Off-Label Drugs for Patients With Advanced Solid Tumors
Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC
Romiplostim for Chemotherapy-Induced Thrombocytopenia
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo